Skip to main content

Reviews from Journal of Experimental & Clinical Cancer Research

Below is a summary of all reviews published in JECCR

Page 5 of 7

  1. Oncogenes derived from the neurotrophin receptor tropomyosin-related kinase TrkA act as drivers in sub-populations of a wide-range of human cancers. This, combined with a recent report that both adult and chil...

    Authors: Antonietta Rosella Farina, Lucia Cappabianca, Pierdomenico Ruggeri, Luciana Gneo, Cristina Pellegrini, Maria-Concetta Fargnoli and Andrew Reay Mackay
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:119
  2. Cancer stem cells (CSCs) or tumor-initiating cells (TICs) represent a small population of cancer cells with self-renewal and tumor-initiating properties. Unlike the bulk of tumor cells, CSCs or TICs are refrac...

    Authors: Mei Yi, Junjun Li, Shengnan Chen, Jing Cai, Yuanyuan Ban, Qian Peng, Ying Zhou, Zhaoyang Zeng, Shuping Peng, Xiaoling Li, Wei Xiong, Guiyuan Li and Bo Xiang
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:118

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2018 37:155

  3. Immune checkpoints include stimulatory and inhibitory checkpoint molecules. In recent years, inhibitory checkpoints, including cytotoxic T lymphocyte–associated antigen 4 (CTLA-4), programmed cell death protei...

    Authors: Feng Xu, Tianqiang Jin, Yuwen Zhu and Chaoliu Dai
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:110
  4. Transfer RNAs (tRNAs), traditionally considered to participate in protein translation, were interspersed in the entire genome. Recent studies suggested that dysregulation was observed in not only tRNAs, but al...

    Authors: Shi-qiong Huang, Bao Sun, Zong-ping Xiong, Yan Shu, Hong-hao Zhou, Wei Zhang, Jing Xiong and Qing Li
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:101
  5. Radioresistance is a major factor leading to the failure of radiotherapy and poor prognosis in tumor patients. Following the application of radiotherapy, the activity of various metabolic pathways considerably...

    Authors: Le Tang, Fang Wei, Yingfen Wu, Yi He, Lei Shi, Fang Xiong, Zhaojian Gong, Can Guo, Xiayu Li, Hao Deng, Ke Cao, Ming Zhou, Bo Xiang, Xiaoling Li, Yong Li, Guiyuan Li…
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:87
  6. In the advent of Immune Checkpoint inhibitors (ICI) and of CAR-T adoptive T-cells, the new frontier in Oncology is Cancer Immunotherapy because of its ability to provide long term clinical benefit in metastati...

    Authors: Luigi Aurisicchio, Matteo Pallocca, Gennaro Ciliberto and Fabio Palombo
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:86
  7. The epidermal growth factor receptor (EGFR) plays important roles in cell survival, growth, differentiation, and tumorigenesis. Dysregulation of the EGFR is a common mechanism in cancer progression especially ...

    Authors: Meng-Shih Weng, Jer-Hwa Chang, Wen-Yueh Hung, Yi-Chieh Yang and Ming-Hsien Chien
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:61
  8. With cancer stem cells (CSCs) became the research hotspot, emerging studies attempt to reveal the functions of these special subsets in tumorigenesis. Although various approaches have been used in CSCs researc...

    Authors: Y. T. Luo, J. Cheng, X. Feng, S. J. He, Y. W. Wang and Q. Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:38
  9. Current treatment for acute myeloid leukemia (AML) is less than optimal, but increased understanding of disease pathobiology and genomics has led to clinical investigation of novel targeted therapies and ratio...

    Authors: Silvia Boffo, Angela Damato, Luigi Alfano and Antonio Giordano
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:36
  10. Since Salinomycin (Sal) emerged its ability to target breast cancer stem cells in 2009, numerous experiments have been carried out to test Sal’s anticancer effects. What deserve to be mentioned is that Sal can...

    Authors: Jiang Jiang, Hailong Li, Eskandar Qaed, Jing Zhang, Yushu Song, Rong Wu, Xinmiao Bu, Qinyan Wang and Zeyao Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:26
  11. Antibody-Drug Conjugates (ADCs) are a class of cancer therapeutics that combines antigen specificity and potent cytotoxicity in a single molecule as they are comprised of an engineered antibody linked chemical...

    Authors: Cécile Chalouni and Sophia Doll
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:20
  12. Cancer remains as one of the leading cause of death worldwide. The development of cancer involves an intricate process, wherein many identified and unidentified factors play a role. Although most studies have ...

    Authors: Nyanbol Kuol, Lily Stojanovska, Vasso Apostolopoulos and Kulmira Nurgali
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:5
  13. Osteosarcoma (OS) is the most common primary malignant tumor of bone, which preferentially develops lung metastasis. Although standard chemotherapy has significantly improved long-term survival over the past f...

    Authors: Angela De Luca, Lavinia Raimondi, Francesca Salamanna, Valeria Carina, Viviana Costa, Daniele Bellavia, Riccardo Alessandro, Milena Fini and Gianluca Giavaresi
    Citation: Journal of Experimental & Clinical Cancer Research 2018 37:2
  14. Telomeres are specialized nucleoprotein structures responsible for protecting chromosome ends in order to prevent the loss of genomic information. Telomere maintenance is required for achieving immortality by ...

    Authors: Luca Pompili, Carlo Leonetti, Annamaria Biroccio and Erica Salvati
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:189
  15. Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomat...

    Authors: Haige Ye, Aakash Desai, Dongfeng Zeng, Krystle Nomie, Jorge Romaguera, Makhdum Ahmed and Michael L. Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:185
  16. Glioblastoma Multiforme is the deadliest type of brain tumor and is characterized by very poor prognosis with a limited overall survival. Current optimal therapeutic approach has essentially remained unchanged...

    Authors: Claudia Abbruzzese, Silvia Matteoni, Michele Signore, Luca Cardone, Kavindra Nath, Jerry D. Glickson and Marco G. Paggi
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:169
  17. CircRNAs are a class of RNA molecules that structurally form closed loops. CircRNAs are abundant in eukaryotic transcripts and show certain levels of tissue and cell specificity. CircRNAs have been suggested t...

    Authors: Yu Zhang, Wei Liang, Peng Zhang, Jingyan Chen, Hui Qian, Xu Zhang and Wenrong Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:152
  18. The increasing use of genomics to define the pattern of actionable mutations and to test and validate new therapies for individual cancer patients, and the growing application of liquid biopsy to dynamically t...

    Authors: Nicola Silvestris, Gennaro Ciliberto, Paolo De Paoli, Giovanni Apolone, Maria Luisa Lavitrano, Marco A. Pierotti and Giorgio Stanta
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:128
  19. Elucidation of mechanisms regulating bone metastasis has progressed significantly in recent years and this has translated to many new therapeutic options for patients with bone metastatic cancers. However, the...

    Authors: Andrew S. Gdowski, Amalendu Ranjan and Jamboor K. Vishwanatha
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:108
  20. Worldwide breast cancer is the most common cancer in women. For many years clinicians and the researchers are examining and exploring various therapeutic modalities for breast cancer. Yet the disease has remai...

    Authors: Urmila Banik, Subramani Parasuraman, Arun Kumar Adhikary and Nor Hayati Othman
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:98
  21. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a prokaryotic adaptable immune mechanism used by many bacteria and archaea to protect themselves from foreign nucleic acids. This complex s...

    Authors: A. Biagioni, A. Chillà, E. Andreucci, A. Laurenzana, F. Margheri, S. Peppicelli, M. Del Rosso and G. Fibbi
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:80
  22. The immune response is a key factor in the fight against HPV infection and related cancers, and thus, HPV is able to promote immune evasion through the expression of oncogenes. In particular, the E5 oncogene i...

    Authors: Antonio Carlos de Freitas, Talita Helena Araújo de Oliveira, Marconi Rego Barros Jr. and Aldo Venuti
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:71
  23. Multiple myeloma (MM) is a clonal plasma-cell neoplastic disorder arising from an indolent premalignant disease known as monoclonal gammopathy of undetermined significance (MGUS). MM is a biologically complex ...

    Authors: Anna Shvartsur, Kevin B. Givechian, Hermes Garban and Benjamin Bonavida
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:62
  24. Deptor is an important protein that belongs to the mTORC1 and mTORC2 complexes, able to interact with mTOR and to inhibit its kinase activity. As a natural mTOR inhibitor, Deptor is involved in several molecul...

    Authors: Valeria Catena and Maurizio Fanciulli
    Citation: Journal of Experimental & Clinical Cancer Research 2017 36:12
  25. Identifying appropriate preclinical cancer models remains a major challenge in increasing the efficiency of drug development. A potential strategy to improve patient outcomes could be selecting the ‘right’ tre...

    Authors: Luca Pompili, Manuela Porru, Carla Caruso, Annamaria Biroccio and Carlo Leonetti
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:189
  26. The mammalian sirtuin family has attracted tremendous attention over the past few years as stress adaptors and post-translational modifier. They have involved in diverse cellular processes including DNA repair...

    Authors: Zhen Mei, Xian Zhang, Jiarong Yi, Junjie Huang, Jian He and Yongguang Tao
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:182
  27. DNA damage response (DDR) defects imply genomic instability and favor tumor progression but make the cells vulnerable to the pharmacological inhibition of the DNA repairing enzymes. Targeting cellular proteins...

    Authors: Aniello Cerrato, Francesco Morra and Angela Celetti
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:179
  28. Epigenetic silencing of tumor suppressor genes (TSGs) through DNA methylation and histone changes is a main hallmark of cancer. Ubiquitin-like with PHD and RING Finger domains 1 (UHRF1) is a potent oncogene overe...

    Authors: Mahmoud Alhosin, Ziad Omran, Mazin A. Zamzami, Abdulrahman L. Al-Malki, Hani Choudhry, Marc Mousli and Christian Bronner
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:174
  29. Among several types of tumor, lung cancer is considered one of the most fatal and still the main cause of cancer-related deaths. Although chemotherapeutic agents can improve survival and quality of life compar...

    Authors: Mohanad Aldarouish and Cailian Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:157
  30. Exosomes are nanoscale extracellular membrane vesicles that are created by the fusion of an intracellular multivesicular body with the cell membrane. They are widely distributed in serum, urine, saliva and oth...

    Authors: Wenting Xu, Zhen Yang and Nonghua Lu
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:156
  31. Major currently used anticancer therapeutics either directly damage DNA or target and upset basic cell division mechanisms like DNA replication and chromosome segregation. These insults elicit activation of ce...

    Authors: Roberta Visconti, Rosa Della Monica and Domenico Grieco
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:153
  32. The advent of targeted therapeutics in human cancer has begun to find novel druggable targets and, in this context, the endothelin-1 receptor (ET-1R), namely ETA receptor (ETAR) and ETB receptor, among the GPCR f...

    Authors: Laura Rosanò and Anna Bagnato
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:121
  33. Recent progress in the Nerve Growth Factor (NGF) research has shown that this factor acts not only outside its classical domain of the peripheral and central nervous system, but also on non-neuronal and cancer...

    Authors: Luigi Aloe, Maria Luisa Rocco, Bijorn Omar Balzamino and Alessandra Micera
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:116
  34. The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outc...

    Authors: Alessandra Fabi, Paola Malaguti, Sabrina Vari and Francesco Cognetti
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:104
  35. The role of immune response is emerging as a key factor in the complex multistep process of cancer. Tumor microenvironment contains different types of immune cells, which contribute to regulate the fine balanc...

    Authors: Laura Paladini, Linda Fabris, Giulia Bottai, Carlotta Raschioni, George A. Calin and Libero Santarpia
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:103
  36. The transcription factor Yin Yang 1 (YY1) is frequently overexpressed in cancerous tissues compared to normal tissues and has regulatory roles in cell proliferation, cell viability, epithelial-mesenchymal tran...

    Authors: Samantha Kaufhold, Hermes Garbán and Benjamin Bonavida
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:84
  37. A widespread decrease of mature microRNAs is often observed in human malignancies giving them potential to act as tumor suppressors. Thus, microRNAs may be potential targets for cancer therapy. The global miRN...

    Authors: Aymone Gurtner, Emmanuela Falcone, Francesca Garibaldi and Giulia Piaggio
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:45
  38. Acting as inflammatory mediators, tumor oncogenes or suppressors, microRNAs are involved in cell survival, death, epithelial–mesenchymal transition and metastasis, etc. Investigating the communication between ...

    Authors: Yudan Chi and Dongming Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:43
  39. Temozolomide (TMZ), an alkylating agent, is widely used for treating primary and recurrent high-grade gliomas. However, the efficacy of TMZ is often limited by the development of resistance. Recently, studies ...

    Authors: Yuanliang Yan, Zhijie Xu, Shuang Dai, Long Qian, Lunquan Sun and Zhicheng Gong
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:23
  40. Pigment epithelium-derived factor (PEDF) is a secreted glycoprotein and a non-inhibitory member of the serine protease inhibitor (serpin) family. It is widely expressed in human fetal and adult tissues but its...

    Authors: Louiza Belkacemi and Shaun Xiaoliu Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:4
  41. Despite the global decline in the incidence and mortality of gastric cancer, it remains one of the most common malignant tumors of the digestive system. Although surgical resection is the preferred treatment f...

    Authors: Wenting Xu, Zhen Yang and Nonghua Lu
    Citation: Journal of Experimental & Clinical Cancer Research 2016 35:1
  42. The treatment of cancer presents a clinical challenge both in human and veterinary medicine. Chemotherapy protocols require the use of toxic drugs that are not always specific, do not selectively target cancer...

    Authors: Megan Walsh, Stefano Fais, Enrico Pierluigi Spugnini, Salvador Harguindey, Tareq Abu Izneid, Licia Scacco, Paula Williams, Cinzia Allegrucci, Cyril Rauch and Ziad Omran
    Citation: Journal of Experimental & Clinical Cancer Research 2015 34:93
  43. Increased understanding of the genetic aetiology of advanced non-small-cell lung cancer (aNSCLC) has facilitated personalised therapies that target specific molecular aberrations associated with the disease. B...

    Authors: James Sherwood, Simon Dearden, Marianne Ratcliffe and Jill Walker
    Citation: Journal of Experimental & Clinical Cancer Research 2015 34:92
  44. Zebrafish represent a vertebrate model organism that has been widely, and increasingly, employed over the last decade in the study of developmental processes, wound healing, microbe-host interactions, and drug...

    Authors: Shuai Zhao, Jian Huang and Jun Ye
    Citation: Journal of Experimental & Clinical Cancer Research 2015 34:80
  45. A class of small non-coding RNAs, the microRNAs (miRNAs), have recently attracted great attention in cancer research since they play a central role in regulation of gene-expression and miRNA aberrant expressio...

    Authors: Germana Falcone, Armando Felsani and Igea D’Agnano
    Citation: Journal of Experimental & Clinical Cancer Research 2015 34:32